PIM-1 inhibition with AZD1208 to prevent osimertinib-induced resistance in EGFR-mutation positive non-small cell lung cancer

Jillian Wilhelmina Paulina Bracht¹, Niki Karachaliou¹,², Jordi Berenguer¹, Manuel Fernandez-Bruno², Martyna Filipska³, Carlos Pedraz-Valdunciel³, Carles Codony-Servat¹, Jordi Codony-Servat¹, Rafael Rosell¹,³,⁴,⁵

¹Pangaea Oncology, Laboratory of Molecular Biology, Quirón-Dexeus University Institute, Barcelona 08028, Spain. ²Instituto Oncológico Dr Rosell (IOR), University Hospital Sagrat Cor, QuironSalud Group, Barcelona 08029, Spain. ³Institut d’Investigació en Ciències Germans Trias i Pujol, Badalona 08916, Spain. ⁴Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona 08916, Spain. ⁵Instituto Oncológico Dr Rosell (IOR), Quirón-Dexeus University Institute, Barcelona 08028, Spain.

Correspondence to: Prof. Rafael Rosell, Institut Català d’Oncologia, Hospital Germans Trias i Pujol, Badalona 08916, Spain. E-mail: rosell@iconcologia.net


Received: 30 Dec 2018  Accepted: 27 Feb 2019  Published: 26 Mar 2019

Science Editor: Yaguang Xi  Copy Editor: Cai-Hong Wang  Production Editor: Huan-Liang Wu

Abstract

Aim: The progression free survival of non-small cell lung cancer (NSCLC) patients has been doubled over the last years, but still single epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) lead to incomplete responses. Compensatory signaling pathways are activated upon single EGFR TKIs. We have shown that compounds, which inhibit these pathways, are synergistic with EGFR TKIs. Proviral integration site for Moloney murine leukemia virus (PIM) has been connected to cancer therapy resistance, being involved in receptor tyrosine kinase, signal transducer and activator of transcription 3 (STAT3) and interleukin-6 signaling. We hypothesized that combined PIM and EGFR inhibition may improve the upfront therapy of EGFR-mutation positive NSCLC.

Methods: We reviewed the literature on PIM kinases, and performed cell viability assays, gene expression analyses, and immunoblotting experiments to reveal the mechanisms of action of the PIM inhibitor (AZD1208) alone and combined with osimertinib in five EGFR-mutation positive NSCLC cell lines.

Results: Osimertinib alone induced the activation of signal transducer and activator of transcription 3 (STAT3) as well as other signaling nodes. Combined osimertinib and AZD1208 yielded moderate synergistic effects in all
NSCLC cell lines investigated. Among the EGFR-mutation positive cell lines examined, the H1975 and PC9 cell lines had the highest PIM1 and STAT3 mRNA expression. The combination decreased the osimertinib-induced STAT3 phosphorylation.

Conclusion: This study provides a short review on PIM kinases, and shows our results of combined PIM and EGFR inhibition in EGFR-mutation positive NSCLC cell lines. The combination was moderately synergistic but decreased STAT3 phosphorylation, an important signaling node in therapy resistance.

Keywords: Non-small cell lung cancer, EGFR, PIM-1, AZD1208, tyrosine kinase inhibitors

INTRODUCTION

Activation of the epidermal growth factor receptor (EGFR) leads to downstream induction of signaling pathways, including phosphatidylinositol 3-kinase/AKT, Ras/mitogen-activated protein kinase and Janus kinase 2 (JAK2)/signal transducer and activator of transcription 3 (STAT3) [Figure 1]. Consequently, these pathways stimulate cell proliferation, cell motility, cell cycle progression and cell survival\(^1\). EGFR mutations were discovered in 2004\(^1\). This finding has radically changed the therapy of EGFR-mutation positive non-small cell lung cancer (NSCLC) patients, replacing standard chemotherapy with EGFR tyrosine kinase inhibitors (TKIs)\(^1,2\). Treatment with first-, second-, and third-generation EGFR TKIs has significantly improved the progression free survival of NSCLC patients, harboring EGFR mutations\(^1\). The third-generation EGFR TKI, osimertinib is now the standard first-line therapy of these patients\(^5\). However, although initially effective, monotherapy with EGFR TKIs, including osimertinib, triggers intrinsic or acquired resistance pathways\(^6-8\), and the patients eventually succumb to their disease.

Signaling nodes, including signal transducer and activator of transcription 3 (STAT3) and Src/Yes-associated protein 1 (YAP1), are not abrogated or even activated upon EGFR blockade. Moreover, besides EGFR, other receptor tyrosine kinases (RTKs) are present and induce downstream signaling, independent of EGFR inhibition\(^6-13\). We have demonstrated that simultaneous inhibition of EGFR, STAT3 and Src-YAP1 was highly synergistic in vitro and in vivo. Moreover, multiple RTKs and non-RTKs were up regulated at baseline or after treatment with EGFR TKIs, limiting their efficacy\(^6-8\). Proviral integration site for Moloney murine leukemia virus-1 (PIM-1) is a serine/threonine kinase, involved in cell cycle progression, cell growth, cell survival and therapy resistance. PIM-1 is activated in various types of cancer, amongst which prostate\(^14-16\), colorectal\(^15,17-19\), triple negative breast cancer (TNBC)\(^20,21\), hematologic malignancies\(^22-24\), neuroblastoma\(^25\) and lung cancer\(^26\). For this reason, PIM kinases could provide a common target for the treatment of diverse malignancies.

PIM activation is induced by changes in the tumor microenvironment, such as hypoxia, and causes resistance to antiangiogenic drugs\(^15\). The combination of PIM inhibitors with antiangiogenic compounds, down regulates the expression of hypoxia inducible factor 1 (HIF1) and decreases tumor cell proliferation, the formation of tumor vasculature and the ability of the cells to metastasize\(^15\). A second study has also shown the involvement of PIM kinases in therapy resistance through hypoxia. Although the authors in this study propose a HIF1-independent, nuclear factor-erythroid 2 p45-related factor 2 induced hypoxia, PIM kinase inhibitors are again the solution to prevent therapy resistance and induce cell death in different tumor types\(^27\).

PIM-1 is involved in RTKs, STAT3 and interleukin-6 (IL-6) signaling [Figure 1]. Specifically, STAT proteins bind to the promoter of the PIM-1 gene, and increase PIM-1 expression. A feedback loop, in turn, regulates the expression of STAT proteins\(^14,15,18,21,24,29\). Considering the fact that there are no approved STAT3 inhibitors, the combination of EGFR TKIs with a PIM-1 inhibitor could be of interest to block STAT3
In prostate and gastric cancer, the efficacy of AKT inhibitors is attenuated by PIM-1 signaling, which upregulates the expression of MET, ERBB2 and other RTKs. Combined AKT and PIM-1 inhibition is synergistic in preclinical models \[16,30\]. Similarly, in the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), the efficacy of the Bruton’s tyrosine kinase inhibitor ibrutinib, was attenuated in the presence of PIM-1 mutations. In addition, chronic exposure of an ABC-DLBCL cell line to ibrutinib increased PIM-1 expression, and the combination of ibrutinib with the pan-PIM inhibitor (AZD1208) showed synergistic effects \[24\]. Finally, in MET amplified NSCLC and gastric cancer cell lines, PIM-1 was identified as a mechanism of resistance to MET inhibitors. Treatment of MET inhibitor-resistant cells with PIM inhibitors restored sensitivity to MET inhibition, both in culture and in xenograft models \[26\].

Several PIM inhibitors have been developed, and can be categorized into first- and next generation inhibitors. AZD1208 falls in the latter category, and inhibits all isoforms of the PIM kinase (1, 2 and 3). AZD1208 has been shown to improve outcome to radiation therapy in castrate-resistant prostate cancer cells \[14\]. Similarly, in the activated B cell-like (ABC) subtype of diffuse large B cell lymphoma (DLBCL), the efficacy of the Bruton’s tyrosine kinase inhibitor ibrutinib, was attenuated in the presence of PIM-1 mutations. In addition, chronic exposure of an ABC-DLBCL cell line to ibrutinib increased PIM-1 expression, and the combination of ibrutinib with the pan-PIM inhibitor (AZD1208) showed synergistic effects \[24\]. Finally, in MET amplified NSCLC and gastric cancer cell lines, PIM-1 was identified as a mechanism of resistance to MET inhibitors. Treatment of MET inhibitor-resistant cells with PIM inhibitors restored sensitivity to MET inhibition, both in culture and in xenograft models \[26\].

Several PIM inhibitors have been developed, and can be categorized into first- and next generation inhibitors. AZD1208 falls in the latter category, and inhibits all isoforms of the PIM kinase (1, 2 and 3). AZD1208 has been shown to improve outcome to radiation therapy in castrate-resistant prostate cancer cells \[14\]. Moreover, PIM-1 levels were correlated to MET expression in both cell lines and patient-derived tumor samples, driving migration and invasion of cancer cells. Patient-derived tissues from a phase 1 clinical trial (ClinicalTrials.gov Identifier: NCT01489722), exploring the safety, tolerability, pharmacokinetics and efficacy of AZD1208 in acute myeloid leukemia, confirmed the mechanism of action of PIM-1 through MET regulation \[31\].

---

**Figure 1.** We present our initial literature-based model of EGFR-mutation positive NSCLC tumor cells, treated with single TKIs, and the parallel compensatory pathways that are being activated. Upon TKI treatment the downstream PI3K/AKT and RAS/MAPK pathways - in light grey - are inhibited, limiting the ability of the cells for proliferation and survival. However, our previous work has shown that this inhibition is the direct cause of the activation of the JAK2/STAT3 and Src-YAP1 pathways, and cannot abrogate coexpressed RTKs (e.g., MET, CDCP1) on the cell membrane. This in turn causes increased cell proliferation and survival, and thus leads to therapy resistance. PIM is an important signaling node in this network, potentially activated through IL-6/STAT3 and/or hypoxia. PIM was shown to be activated in multiple tumor types, and may therefore provide a druggable target for various tumor types. EGFR: epidermal growth factor receptor; NSCLC: non-small cell lung cancer; TKI: tyrosine kinase inhibitor; PI3K: phosphatidylinositol 3-kinase; MAPK: mitogen-activated protein kinase; JAK2: Janus kinase 2; STAT3: signal transducer and activator of transcription 3; YAP1: Yes-associated protein 1; RTK: receptor tyrosine kinase; PIM: proviral integration site for Moloney murine leukemia virus; IL-6R: interleukin 6 receptor; CDCP1: CUB domain-containing protein 1; EphA2: EPH receptor A2; PXN: Paxillin
The ability of AZD1208 to induce cell cycle arrest and apoptosis by inhibition of all PIM kinase isoforms indicates its potential as an anticancer treatment. Previous publications have shown that PIM inhibition augments the efficacy of targeted therapies in diverse tumor types. Therefore, dual PIM-1 and EGFR inhibition might modulate cell survival pathways and block progression and growth of cancer cells, by preventing the EGFR TKI-induced STAT3 and RTKs activation in EGFR-mutation positive NSCLC cell lines\[^{[6-8]}\]. This research aims to evaluate whether the pan-PIM inhibitor AZD1208 improves the efficacy of osimertinib in EGFR-mutation positive cell lines.

**METHODS**

**Chemicals and reagents**

Human lung adenocarcinoma PC-9 cells, harboring EGFR exon 19 deletion and 11-18 cells, harboring EGFR exon 21 L858R mutation were provided by F. Hoffmann-La Roche Ltd. (Basel, Switzerland), and by Dr. Mayumi Ono, (Kyushu University, Fukuoka, Japan), respectively. EGFR exon 19 deletion positive HCC4006 and HCC827 cells were purchased from the American Type Culture Collection (ATCC). The H1975 cell line, harboring both EGFR exon 21 L858R and resistant T790M mutation as well as the TNBC MBA-MB-231 cell line were purchased from ATCC. All cell lines were maintained in RPMI (Roswell Park Memorial Institute medium) 1640 supplemented with 1% penicillin/streptomycin/glutamine (Gibco) and 10% fetal bovine serum (FBS; Gibco) in a 5% CO\(_2\) 37 °C cell culture incubator and routinely evaluated for mycoplasma contamination.

The pan-PIM inhibitor, AZD1208, and osimertinib were bought from Selleck Chemicals (Houston, TX, USA). Drugs were prepared in dimethylsulfoxide (DMSO) at a concentration of 10-100 mmol/L stock solutions and stored at -20 °C. Further dilutions were made in culture medium to final concentration before use. All antibodies used in our study, including dilution and company catalog number can be found in Supplementary Table 1. All primers used can be found in Supplementary Table 2.

**Cell viability assay**

Cells were seeded in 96-well plates at the following densities: 1.5 × 10\(^3\) (PC9), 2.0 × 10\(^3\) (H1975) 3.0 × 10\(^3\) (HCC4006, HCC827 and 11-18), and incubated for 24 h, as previously described\[^{[6]}\]. For the combined treatment cells were seeded in 96-well plates at the following densities: 1 × 10\(^3\) (PC9 and H1975), 1.5 × 10\(^3\) (HCC827, HCC4006 and 11-18), and incubated for 24 h. Cell viability was assessed using the 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay (Sigma Aldrich, St Louis, MO, USA). Cells were treated with serial dilutions of the drugs. For the half maximal inhibitory concentration (IC\(_{50}\)) determination, AZD1208 doses ranged from 0-200 μmol/L and treatment lasted 72 h. For the MTT viability assays with a combination of AZD1208 and osimertinib (IC\(_{50}\) were previously obtained) drug doses were as follows: PC9, H1975, HCC4006, HCC827 cells were treated with osimertinib ranging from 0-100 nmol/L, and AZD1208 ranging from 0-100 μmol/L, or with the combination of both. The 11-18 cells were treated with osimertinib ranging from 0-200 nmol/L, and AZD1208 ranging from 0-100 μmol/L, or with the combination of both. The combined treatment lasted 96 h. After treatment incubation, 0.5 mg/mL of MTT reagent was added to the medium in the wells for 2 h at 37 °C and formazan crystals in viable cells were solubilized with 100 μL DMSO and spectrophotometrically quantified using a microplate reader (Varioskan Flash; Thermo Fisher Scientific, Waltham, MA, USA) at 565 nm of absorbance. Fractional survival was then calculated as percentage to control cells. Data of combined drug effects were subsequently analyzed by the Chou and Talalay method\[^{[32,33]}\]. Combination index (CI) values < 1, = 1 and > 1 indicated synergism, additive effect and antagonism, respectively.

**Western blotting**

For immunoblotting experiments, 1.5 million cells were seeded in T75 flasks (Starstedt, Newton, USA). The next day, PC9 and H1975 cells were treated with 24 nmol/L osimertinib, 5 μmol/L AZD1208 and
a combination of both. Untreated cells received an equivalent dose of vehicle (DMSO). After 24 h cells were washed with cold PBS and re-suspended in ice-cold radioimmunoprecipitation assay buffer (50 mmol/L Tris- hydrochloric acid in pH 7.4, 1% Nonidet P-40, 0.5% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 150 mmol/L sodium chloride, 1 mmol/L ethylenediaminetetraacetic acid, 1 mmol/L sodium vanadate and 50 mmol/L sodium fluoride) containing protease inhibitor mixture (Roche Applied Science, Penzberg, Germany). Following cell lysis by sonicaton and centrifugation at 18620 × g for 10 min at 4 °C, the resulting supernatant was collected as the total cell lysate. Briefly, the lysates containing 45 μg proteins were electrophoresed on 10% SDS-polyacrylamide gels (Life Technologies, Carlsbad, CA, USA) and transferred to polyvinylidene difluoride membranes (Bio-Rad laboratories Inc., Hercules, CA, USA). Membranes were blocked in Odyssey blocking buffer (Li-Cor Biosciences, Lincoln, NE, USA). All target proteins were immunoblotted with appropriate primary and horseradish peroxidase (HRP)-conjugated secondary antibodies. Chemiluminescent (HRP-conjugated) bands were detected in a ChemiDoc MP Imaging System (Bio-Rad laboratories Inc.). β-actin was used as an internal control to confirm equal gel loading.

Quantitative real time polymerase chain reaction

RNA was isolated from cell lines using phenol-chloroform-isoamyl alcohol, followed by precipitation with isopropanol in the presence of glycogen and sodium acetate. RNA was re-suspended in water and treated with DNase I to avoid DNA contamination. Complementary DNA (cDNA) was synthesized using moloney murine leukaemia virus reverse transcriptase enzyme. cDNA was added to Taqman Universal Master Mix (Applied Biosystems, Carlsbad, CA, USA) in a 12.5 μL reaction with specific primers and probe for each gene. The primer and probe sets were designed using Primer Express 3.0 Software (Applied Biosystems) according to their Ref Seq (http://www.ncbi.nlm.nih.gov/LocusLink). Gene-specific primers are provided in Chemicals and reagents. Quantification of gene expression was performed using the ABI Prism 7900HT Sequence Detection System (Applied Biosystems) and was calculated according to the comparative Ct method. Final results were determined as follows: 2^-(ΔCt sample-ΔCt calibrator), where ΔCt values of the calibrator and sample are determined by subtracting the Ct value of the target gene from the value of the endogenous gene (β-actin). Commercial RNA controls were used as calibrators (Liver and Lung; Stratagene, La Jolla, CA, USA). In all quantitative experiments, a sample was considered not evaluable when the standard deviation of the Ct values was > 0.30 in two independent analyses. As a result, the number of evaluable samples varied among the genes examined.

RESULTS

Baseline mRNA expression of EGFR-mutation positive cells and sensitivity to PIM inhibition

We first evaluated the baseline mRNA expression of PIM, STAT3 and other relevant genes\(^{[n]}\), in our panel of five EGFR-mutation positive NSCLC cell lines. As can be seen in Figure 2A, both PC9 and H1975 cell lines had higher PIM-1, STAT3 and JAK2 mRNA expression compared to the average gene expression of all five cell lines. Hereafter, cell viability assays were performed and the IC\(_{50}\) of single AZD1208 treatment were determined. The IC\(_{50}\) of osimertinib have been previously calculated and reported\(^{[6]}\). As expected, none of the cell lines was sensitive to single AZD1208 treatment, with IC\(_{50}\) ranging from 17.1 to 23.0 μmol/L [Figure 2B, left panel], while all of them were sensitive to osimertinib\(^{[6]}\) [Figure 2B, right panel].

Combination of osimertinib plus a PIM inhibitor in EGFR-mutation positive cells

Taking into consideration our previous findings, that osimertinib alone induces the activation of resistant signaling nodes\(^{[6]}\), we then tried to evaluate if AZD1208 increases the effect of osimertinib on cell growth inhibition. Dual treatment revealed moderate synergistic effects, with a CoI between 0.79 and 0.85 [Figure 3A, left panel]. The lowestCols and therefore stronger synergism, were seen in the PC9 [CoI of 0.79; 95% confidence interval (CI): 0.66-0.92] and HCC827 (CoI of 0.79; 95%CI: 0.69-0.89) cell lines. A moderate synergism was seen in HCC4006 cells, with a CoI of 0.83 (95%CI: 0.79-0.87). The combination was less
effective, but still moderately synergistic, in the 11-18 (Col of 0.85; 95%CI: 0.69-1.00) and H1975 (Col of 0.85; 95%CI: 0.74-0.96) cell lines [Figure 3A, left panel].

We then tried to see the correlation between signaling nodes and cellular responses after combined treatment with osimertinib plus AZD1208. For this, we selected the PC9 and H1975 cell lines, which distinguished among the rest of the cell lines, having the highest PIM-1, STAT3 and JAK2 mRNA expression [Figure 2A]. Changes in the protein expression of RTKs, STAT3 and other proteins after single osimertinib, AZD1208 or combined treatment were studied, using immunoblotting experiments [Figure 3B, right panel]. The results confirmed our previous findings [6,8], as single osimertinib increased the phosphorylation of CUB-domain-containing protein 1 (CDCP1), YAP1, paxillin and STAT3 in the PC9 and H1975 cell lines. Osimertinib abrogated or diminished EGFR and ERK phosphorylation, but it had no effect on Src phosphorylation [Figure 3B, right panel]. In contrast, single AZD1208 treatment was unable to inhibit activated EGFR and ERK, but in comparison with osimertinib, it induced at a much lower level the phosphorylation of CDCP1, YAP1, STAT3 and paxillin. The combination of osimertinib plus AZD1208, abolished EGFR and ERK activation in both cell lines, but paradoxically, was unable to reverse - or even increased - the osimertinib-induced CDCP1 and YAP1 phosphorylation. To our positive surprise, the double
combination reversed the osimertinib-induced STAT3 phosphorylation in both cell lines, and diminished paxillin and Src phosphorylation in PC9 and H1975 cells, respectively [Figure 3B, right panel]. Overall these data reconfirm our previous findings that, even in oncogene addicted EGFR-mutation positive cancer cells, single EGFR TKIs are insufficient [6-8,34]. Concomitant PIM-1 inhibition may reverse some of the deleterious effects of osimertinib on the activation of oncogenic signaling pathways.

DISCUSSION

Herein, we have reviewed the available literature on PIM and we have found that this kinase is involved in multiple tumor types, including lung cancer [26]. The survival of lung cancer patients has been improved in the last decade due to the availability of new and more effective targeted therapies. EGFR-mutation positive patients are treated with EGFR TKIs, and the last years we have seen the development and approval of three generations of these agents [35]. However, ultimately resistance mechanisms take over and treatment options are not indefinite. Furthermore, about 20% of EGFR-mutation positive patients have intrinsic resistance to EGFR TKIs [34], indicating that molecularly targeted therapy is not a one-size-fits-all approach. Therefore, defining biomarkers of resistance and designing a truly personalized therapy is of great relevance. We have previously seen, and we confirm in the present work, that EGFR TKIs, including osimertinib, induce STAT3 and Src-YAP1 activation [6-8]. Rational double or triple combinations prevented this phenomenon and increased the efficacy of EGFR TKI monotherapy in EGFR-mutation positive models [6-8]. Since PIM was shown to be a key player in IL-6/STAT3 signaling [14,8,21,28,29], we hypothesized that by combining the PIM inhibitor, AZD1208 with osimertinib we may obtain similar results [6-8].
As expected, single AZD1208 was not effective, but the combination of AZD1208 and osimertinib augmented the effect of each drug alone on cell viability in a moderate synergistic manner, in five EGFR-mutation positive cell lines. This synergistic effect is probably due to the AZD1208-based inhibition of resistance pathways. Our model, in Figure 4, indicates that combined EGFR and PIM inhibition does not prevent the activation of all relevant resistance signaling nodes, but it is able to decrease STAT3 phosphorylation. Since currently there are no approved STAT3 inhibitors in clinical use, PIM inhibition merits further investigation in lung cancer as well as other tumor types. AZD1208 is not in clinical development any more \cite{22} and we plan to extend the current work using the pan-PIM inhibitor LGH447 (PIM447). LGH447 has single agent activity, and blocks resistance pathways when combined with standard of care treatments \cite{22,36-38}. The agent is currently being tested in a phase I/II clinical trial (ClinicalTrials.gov Identifier, NCT01456689) for relapsed/refractory multiple myeloma, and safety and efficacy results are awaited.

**DECLARATIONS**

**Authors’ contributions**

Made substantial contributions to conception and design of the study and performed data analysis and interpretation: Bracht JWP, Karachaliou N, Rosell R
Performed data acquisition, as well as provided administrative, technical, and material support: Bracht JWP, Karachaliou N, Berenguer J, Fernandez-Bruno M, Filipska M, Pedraz-Valdunciel C, Codony-Servat C, Codony-Servat J, Rosell R

Availability of data and materials
Not applicable.

Financial support and sponsorship
Work in Dr. Rosell’s laboratory is partially supported by a grant from La Caixa Foundation; an Instituto de Salud Carlos III grant (RESPONSE, PIE16/00011, PI14/01678); a Marie Skłodowska-Curie Innovative Training Networks European Grant (ELBA No 765492); and a Spanish Association Against Cancer (AECC) grant (PROYE18012ROSE).

Conflicts of interest
All authors declared that there are no conflicts of interest.

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Copyright
© The Author(s) 2019.

REFERENCES